Axsome Therapeutics stock analysis
Axsome Therapeutics (0HKF) Share Price & Analysis
0HKF Stock Chart & Stats
- Day’s Range
- $132.00 - $142.98
- 52-Week Range
- $123.16 - $263.93
- Previous Close
- $132.02
- Volume
- N/A
- Average Volume (3M)
- 822
- Market Cap
- $7.42B
- Enterprise Value
- $9.58B
- Total Cash (Recent Filing)
- $313.86M
- Total Debt (Recent Filing)
- $218.67M
- Price to Earnings (P/E)
- ―
- Beta
- 0.97
- Next Earnings
- Mar 01, 2027 (Est.)
- EPS Estimate
- -0.05
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Rapid Commercial Growth
Broad-based commercial growth across the portfolio indicates increasing product adoption and expanding prescriber reach. Strong AUVELITY momentum, supported by prescription growth and payer access, can create a larger revenue base from which Axsome can fund commercialization and future pipeline investment.
High Margins And Improving Losses
Very high gross margins provide attractive product-level economics, while the sharply narrower net loss suggests revenue growth is beginning to translate into operating leverage. If commercial expansion continues without proportional cost increases, the company has a credible path toward improved earnings quality.
Diversified Late-stage CNS Pipeline
A broad CNS pipeline gives Axsome multiple opportunities to extend existing products, enter additional indications and add future revenue streams. Several programs are late stage or approaching regulatory milestones, reducing reliance on a single marketed product and supporting longer-term portfolio durability.
Bears Say
Persistent Cash Consumption
The business is still consuming cash despite improving losses, which limits internally generated funding for commercial expansion and clinical development. Until cash flow turns sustainably positive, Axsome may need to rely on existing liquidity, balance-sheet capacity or capital markets to support its growth plans.
Elevated Leverage
Debt materially exceeds shareholders’ equity, leaving less financial flexibility while earnings remain negative. Elevated leverage can increase the consequences of slower product uptake or higher development spending, and it may constrain capital allocation until operating performance and cash generation improve.
Heavy Commercialization Spending
The company is investing heavily to support launches and broader market adoption, but this spending continues to weigh on profitability. Sustained commercial costs must eventually produce sufficient incremental revenue and operating leverage; otherwise, expansion could prolong losses and cash consumption.
Axsome Therapeutics News
Axsome Advances Adolescent ADHD Study as Investors Await Solriamfetol Data
Axsome Therapeutics Inc. ($AXSM) announced an update on their ongoing clinical study. Study Overview: Axsome Therapeutics, Inc. is studying solriamfetol in adolescents with attention deficit hyperactivity disorder. The official title
0HKF FAQ
What was Axsome Therapeutics’s price range in the past 12 months?
What is Axsome Therapeutics’s market cap?
When is Axsome Therapeutics’s upcoming earnings report date?
How were Axsome Therapeutics’s earnings last quarter?
Is Axsome Therapeutics overvalued?
Does Axsome Therapeutics pay dividends?
What is Axsome Therapeutics’s EPS estimate?
How many shares outstanding does Axsome Therapeutics have?
What happened to Axsome Therapeutics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Axsome Therapeutics?
What is the TipRanks Smart Score and how is it calculated?
Axsome Therapeutics Stock Smart Score
Company Description
Axsome Therapeutics
Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Herriot Tabuteau
- Employees
- 1,346
- Website
- www.axsome.com
- Address
- One World Trade Center, New York City, NY, 10007, US
Axsome Therapeutics (0HKF) Earnings & Revenues
0HKF Company Deck
0HKF Earnings Call
Earnings Call SentimentPositive
The call was strongly positive, with broad-based revenue, prescription, prescriber, payer coverage, and pipeline momentum across AUVELITY, SYMBRAVO, SUNOSI, and multiple late-stage neuroscience programs. The company also reported a substantially reduced net loss and said its cash balance should fund operations through cash flow positivity. Offsetting concerns included higher operating expenses, a still-negative quarterly result, expected seasonal gross-to-net pressure, limited SYMBRAVO coverage, prescription-data capture variability, continuing education needs in Alzheimer's disease agitation, and higher Medicare abandonment.
View all GB:0HKF earnings summaries0HKF Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 5 | 12 |
| Technical Analysis | 1 | 5 | 4 |
| Moving Averages | 4 | 0 | 8 |
